预计癌症将在未来二十年成为全球疾病相关死亡的首要原因，这凸显了对个性化和适应性治疗策略的迫切需要。由于药物疗效的高度可变性以及癌细胞产生耐药性的趋势，这些策略至关重要。本研究利用封装在泡囊体载体中的三种创新荧光聚合物（FP-1、FP-2 和 FP-3），将治疗（化疗和放疗）与荧光成像相结合，研究了治疗诊断纳米技术的潜力。评估这些货物对三种癌细胞系（A549、MCF-7 和 HOb）的细胞毒性作用，并进一步分析以确定它们在特定剂量下使用线性加速器 (LINAC) 增强放射治疗效果的能力。利用荧光显微镜来验证它们在癌性细胞系与健康细胞系中的摄取和定位。结果证实，这些类脂质体货物不仅提高了放射治疗的抗增殖作用，而且证明了荧光聚合物在体外成像中的实际应用。这种双重功能强调了剂量优化的重要性，以最大限度地提高治疗效果，同时最大限度地减少副作用，从而提高癌症治疗的整体疗效。© 2024 作者。高分子生物科学由 Wiley‐VCH GmbH 出版。

Cancer is anticipated to become the pioneer reason of disease-related deaths worldwide in the next two decades, underscoring the urgent need for personalized and adaptive treatment strategies. These strategies are crucial due to the high variability in drug efficacy and the tendency of cancer cells to develop resistance. This study investigates the potential of theranostic nanotechnology using three innovative fluorescent polymers (FP-1, FP-2, and FP-3) encapsulated in niosomal carriers, combining therapy (chemotherapy and radiotherapy) with fluorescence imaging. These cargoes are assessed for their cytotoxic effects across three cancer cell lines (A549, MCF-7, and HOb), with further analysis to determine their capacity to augment the effects of radiotherapy using a Linear Accelerator (LINAC) at specific doses. Fluorescence microscopy is utilized to verify their uptake and localization in cancerous versus healthy cell lines. The results confirmed that these niosomal cargoes not only improved the antiproliferative effects of radiotherapy but also demonstrate the practical application of fluorescent polymers in in vitro imaging. This dual function underscores the importance of dose optimization to maximize therapeutic benefits while minimizing adverse effects, thereby enhancing the overall efficacy of cancer treatments.© 2024 The Author(s). Macromolecular Bioscience published by Wiley‐VCH GmbH.